In the NT GSDMD-treated group we achieved prolonged survival compared to the empty vector-treated mice, yet tumor growth did not cease (Fig. 9g, h), whereas NT GSDMD + IL-1β therapy resulted in tumor suppression and survival of 17% of treated mice (Fig. 9g, h and Supplementary Fig. 12b, c). The gene discussed is GSDMD; the disease is neoplasm.